middle.news
Cyclopharm Extends Technegas® U.S. Patent to 2031, Securing Market Dominance
8:27am on Wednesday 11th of June, 2025 AEST
•
Healthcare
Read Story
Cyclopharm Extends Technegas® U.S. Patent to 2031, Securing Market Dominance
8:27am on Wednesday 11th of June, 2025 AEST
Key Points
Maximum five-year U.S. patent extension granted to 2031
Technegas® maintains exclusive U.S. market position against generics
FDA and USPTO regulatory review confirms patent eligibility
Supports expanded clinical use beyond pulmonary embolism
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cyclopharm (ASX:CYC)
OPEN ARTICLE